Category: China
-
Access Advance strengthens Asia presence with executive IP licensing hires in China, Taiwan
Simon Zhao, formerly at Nokia, and Matt Chen, formerly at Tencent, have joined the Access Advance team, after the patent pool administrator also saw several new Chinese licensors and licensees join its programs this year.
-
Huawei, Qualcomm sign broad, multi-year patent cross-licensing agreement
The deal covers a range of technology fields, including 5G, compute, AI, and networking, and Qualcomm’s purchase of certain Huawei U.S. patents in the areas of compute, AI, networking, and other technologies.
-
Opinion: China’s role in the future of global SEP licensing
In this guest contribution, Via Licensing Alliance’s President Kevin Mack reflects on his last visit to China, and the evolution of patent licensing he has witnessed there.
-
Tesla ‘Sun factory’ apparently at heart of U.S.-Chinese semiconductor technology patent infringement dispute
New York-based Linton Crystal Technologies has sued China’s Zhejiang Jingsheng Mechanical & Electrical Co. over the infringement of seed-lifting technology patents, after the latter reportedly won a bid to supply Tesla with 210mm monocrystalline pullers for its $10.1 billion “Project Crystal Sun” factory.
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Novo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
Hong Kong’s pledge to become IP trading center is ‘game-changer’, but requires more than policy and financing platforms
Lawyers from both HK and China shared their thoughts on Hong Kong’s new Five-Year Plan, which pledges to transform it into a regional IP trading center. While they were generally positive, some were skeptical, highlighting that China’s own experience suggests government policy and trading platforms alone cannot create a liquid market for IP.
-
Daiichi Sankyo loses six CNIPA administrative patent-linkage cases over mirogabalin formulation patents
Daiichi Sankyo has now lost six Chinese patent-linkage cases over generic mirogabalin after the CNIPA found two dosage strengths outside three formulation patents. The rulings show the growing importance of CNIPA’s administrative route for resolving patent disputes before generic launch.
-
China’s top court reinforces human-inventor rule, scope of human-contribution standard likely to be tested in future litigation
China’s top court has reissued the rule that AI itself cannot be an inventor and expressly requires a natural person to make a creative contribution to an AI-assisted invention, bringing an approach already taken by the CNIPA into the judicial framework.
-
Nokia inks new patent licensing deals with Chinese TV makers
In a blog post today, the Head of Nokia’s Consumer Electronics licensing program, Philippe Lanet, said the agreements cover the use of Nokia’s technologies in their video-enabled devices.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledge
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.